Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.57 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | FLT1 | P17948 | 1/20 | 0.55 |
| ▸ | FLT4 | P35916 | 1/20 | 0.55 |
| ▸ | KDR | P35968 | 1/20 | 0.55 |
| ▸ | CCR9 | P51686 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3250357 | 0.87 | ALDH1A1 (0.56) | ALDH1A1TP53KEAP1NFE2L2KMT2A | |
| SCHEMBL2530522 | 0.83 | MEN1 (0.65) | ALDH1A1TP53KMT2ACCR9GAA | |
| SCHEMBL8989887 | 0.83 | LMNA (0.77) | ALDH1A1TP53KMT2ACCR9LMNA | |
| SCHEMBL15354038 | 0.83 | HTT (0.72) | TP53KMT2ACCR9LMNAHTT | |
| SCHEMBL4940505 | 0.80 | CCR9 (0.73) | CCR9LMNAHTT | |
| SCHEMBL8990056 | 0.80 | LMNA (0.61) | ALDH1A1TP53KEAP1NFE2L2KMT2A | |
| SCHEMBL28201 | 0.78 | LMNA (0.57) | ALDH1A1TP53KMT2ACCR9LMNA | |
| SCHEMBL27476 | 0.78 | CRHBP (0.57) | TP53KMT2AFLT1FLT4KDR | |
| SCHEMBL8989935 | 0.78 | LMNA (0.56) | TP53KMT2ACCR9LMNAHTT | |
| SCHEMBL28784798 | 0.78 | LMNA (0.68) | ALDH1A1TP53KEAP1NFE2L2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741519-B2 | Bis-aryl sulfonamides | CHEMOCENTRYX, INC. (US) | 2010-06-22 | — | — | US | claimed |
| US-20080261966-A1 | BIS-ARYL SULFONAMIDES | UNGASHE SOLOMON | 2008-10-23 | — | — | US | claimed |
| EP-1567486-B1 | BIS-ARYL SULFONAMIDES | CHEMOCENTRYX INC (US) | 2008-01-16 | — | — | EP | claimed |
| US-7227035-B2 | Bis-aryl sulfonamides | CHEMOCENTRYX (US) | 2007-06-05 | — | — | US | claimed |
| US-8642808-B2 | Bis-aryl sulfonamides | CHEMOCENTRYX, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20110257183-A1 | BIS-ARYL SULFONAMIDES | UNGASHE SOLOMON | 2011-10-20 | — | — | US | disclosed |
| US-20100227902-A1 | BIS-ARYL SULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2010-09-09 | — | — | US | disclosed |
| US-7741519-B2 | Bis-aryl sulfonamides | CHEMOCENTRYX, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| EP-1776347-B1 | SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI AVENTIS (FR) | 2010-05-26 | — | — | EP | disclosed |
| US-20080261966-A1 | BIS-ARYL SULFONAMIDES | UNGASHE SOLOMON | 2008-10-23 | — | — | US | disclosed |
| US-7396958-B2 | Sulphonamide derivatives, their preparation and their therapeutic application | SANOFI AVENTIS (FR) | 2008-07-08 | — | — | US | disclosed |
| US-7335653-B2 | Chemokine receptor antagonists; CCR9-mediated disorders such as inflammatory and autoimmune diseases | CHEMOCENTRYX, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| EP-1567486-A2 | BIS-ARYL SULFONAMIDES | Chemocentryx (US) | 2005-08-31 | — | — | EP | disclosed |
| US-20050137179-A1 | Bis-aryl sulfonamides | CHEMOCENTRYX, INC. | 2005-06-23 | — | — | US | disclosed |
| WO-2004085384-A2 | BIS-ARYL SULFONAMIDES | CHEMOCENTRYX (US) | 2004-10-07 | — | — | WO | disclosed |
| US-20040167113-A1 | Bis-aryl sulfonamides | CHEMOCENTRYX, INC. | 2004-08-26 | — | — | US | disclosed |
| US-5578633-A | VASOPRESSIN AND OXYTOCIN ANTAGONISTS | SANOFI (FR) | 1996-11-26 | — | — | US | disclosed |
| US-5481005-A | N-sulfonylindoline derivatives, their preparation and the pharmaceutical compositions in which they are present | SANOFI (FR) | 1996-01-02 | — | — | US | disclosed |
| US-5397801-A | Affinity for vasopressin and ocytocin receptors; disorders of nervous, cardiovascular and gastrointestinal systems | SANOFI (FR) | 1995-03-14 | — | — | US | disclosed |
| US-5338755-A | Have affinity for vasopressin and ocytocin receptors; intermediates for drugs that act on central nervous system | ELF SANOFI (FR) | 1994-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227902-A1 | BIS-ARYL SULFONAMIDES | CCR2, CXCR2, CCL2 | ALDH1A1 2054/4885TP53 3183/4885KEAP1 2690/4885 |
| US-20050137179-A1 | Bis-aryl sulfonamides | CCR2, CXCR2, CCL2 | ALDH1A1 2054/4885TP53 3183/4885KEAP1 2690/4885 |
| US-20040167113-A1 | Bis-aryl sulfonamides | CCR2, CXCR2, CCL2 | ALDH1A1 2054/4885TP53 3183/4885KEAP1 2690/4885 |
| US-20110257183-A1 | BIS-ARYL SULFONAMIDES | CCR2, CXCR2, CCL2 | ALDH1A1 2054/4885TP53 3183/4885KEAP1 2690/4885 |
| US-20080261966-A1 | BIS-ARYL SULFONAMIDES | CCR2, CXCR2, CCL2 | ALDH1A1 2054/4885TP53 3183/4885KEAP1 2690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.